Ion Niculescu-Duvaz

This inventor holds 16 USPTO granted patents, plus 2 CIPO patents and 5 EPO patents. Top assignees: Cancer Research Technology Limited, Institute of Cancer Research: Royal Cancer Hospital (the), The Institute of Cancer Research: Royal Cancer Hospital. Active years: 1999-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ion Niculescu-Duvaz. Retrieved from https://idiyas.com/inventor/ion-niculescu-duvaz

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 25.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 5.5

ph-index = 8

Forward Citations = 188(Granted Patents)

Location History:

Surrey, GB (2014)
Sutton, GB (1999 - 2019)

Company Filing History:

14 out of 268

Cancer Research Technology Limited

patents

10 out of 13

Institute of Cancer Research: Royal Cancer Hospital (the)

patents

3 out of 54

The Institute of Cancer Research: Royal Cancer Hospital

patents

4. 1 out of 126

Astex Therapeutics Limited

patents

5. 1 out of 62

Cancer Research Campaign Technology Limited

patents

6. 1 out of 3

The Wellcome Trust Limited

patents

where one patent can have more than one assignee

Years Active: 1999-2019

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10167282 - 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido [2, 3-B]pyrazin- 8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer (2019-01-01),

2. 9820976 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2017-11-21),

3. 9725447 - 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as RAF inhibitors for the treatment of cancer (2017-08-08),

4. 9540372 - Pyrido[2,3-b]pyrazin-8-substituted compounds and their use (2017-01-10),

5. 9439893 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2016-09-13),

6. 9155737 - Pyrido[2,3-B]pyrazin-8-substituted compounds and their use (2015-10-13),

7. 9120789 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2015-09-01),

8. 8912191 - Pyrido[2,3-B]pyrazin-8-substituted compounds and their use (2014-12-16),

9. 8815896 - 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy (2014-08-26),

10. 8546387 - Pyrido[2,3-b]pyrazin-8-substituted compounds and their use (2013-10-01),

11. 8383816 - Aryl-quinolyl compounds and their use (2013-02-26),

12. 8198279 - Pyrido[2,3-b]pyrazin-8-substituted compounds and their use (2012-06-12),

13. 7951819 - Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds (2011-05-31),

14. 7737152 - 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds (2010-06-15),

15. 7235585 - Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs (2007-06-26),

Title: Ion Niculescu-Duvaz: Innovator in Cancer Therapeutics

Introduction

Ion Niculescu-Duvaz is a prominent inventor based in Sutton, GB, known for his significant contributions to the field of cancer therapeutics. With a total of 16 patents to his name, he has made remarkable strides in developing innovative compounds aimed at treating various forms of cancer.

Latest Patents

His latest patents include groundbreaking work on 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives, which serve as RAF inhibitors for cancer treatment. This invention focuses on therapeutic compounds that inhibit RAF, including BRAF and CRAF, and addresses disorders such as malignant melanoma, colorectal carcinoma, and pancreatic adenocarcinoma. Another notable patent involves 1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea, which is particularly useful in treating cancers driven by mutant RAS.

Career Highlights

Throughout his career, Ion has worked with esteemed organizations such as Cancer Research Technology Limited and the Institute of Cancer Research, Royal Cancer Hospital. His work has significantly impacted the development of therapeutic strategies for cancer treatment.

Collaborations

Ion has collaborated with notable individuals in the field, including Caroline Joy Springer and Dan Niculescu-Duvaz, contributing to a rich exchange of ideas and advancements in cancer research.

Conclusion

Ion Niculescu-Duvaz stands out as a key figure in the innovation of cancer therapeutics, with a strong portfolio of patents that reflect his dedication to improving treatment options for patients. His work continues to inspire advancements in the medical field.

Profile summary based on public USPTO records.